MedTrace Logo

Effects of Fatty Acid Supplementation on Substance Dependent Individuals

NCT00312455 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-12

No results posted yet for this study

Summary

Many substance dependent individuals continue to abuse a variety of substances during treatment for their disorder. Often, substance dependent individuals are co-diagnosed with depression and violence problems. Supplements of n-3 polyunsaturated fatty acids (PUFAs) may play a role in treating individuals with such substance abuse problems. The purpose of this study is to evaluate the effectiveness of the n-3 PUFAs eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA) in treating relapse, aggression, and depression in substance dependent individuals.

Conditions

  • Substance-related Disorders

Interventions

DRUG

Pro-eicosapentaenoic acid (EPA)

450 mg 5x/day

DRUG

Pro-docosapentaenoic acid (DPA)

100mg 5x/day

DRUG

Placebo

5 capsules/day

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Laure Buydens-Branchey, MD · VA New York Harbor Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-07-31
Completion
2005-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00312455 on ClinicalTrials.gov